|
Sponsored Research and License Agreements (Details) (Collaborations, USD $)
|
1 Months Ended | 6 Months Ended | 1 Months Ended | 6 Months Ended | 1 Months Ended | 1 Months Ended | 1 Months Ended | 3 Months Ended | 1 Months Ended | 6 Months Ended | 1 Months Ended | 3 Months Ended | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Apr. 30, 2010
AstraZeneca
|
Jun. 30, 2012
AstraZeneca
item
|
Apr. 30, 2010
AstraZeneca
Single unit of accounting
unit
|
Sep. 30, 2010
AstraZeneca
Single unit of accounting
|
Sep. 30, 2010
AstraZeneca
Milestone achieved
|
Sep. 29, 2010
AstraZeneca
Specified events
|
Sep. 29, 2010
AstraZeneca
Specified sales levels
|
Aug. 31, 2002
Daiichi Sankyo
|
Jun. 30, 2012
Daiichi Sankyo
|
Jan. 31, 2012
Daiichi Sankyo
Milestone achieved
|
Jul. 31, 2011
Merck Serono
|
Sep. 30, 2011
Merck Serono
|
Aug. 31, 2011
BerGenBio
|
Jun. 30, 2012
BerGenBio
|
Jul. 31, 2012
R256
|
Jun. 30, 2012
R256
|
|
| Collaborations | ||||||||||||||||
| Number of significant active collaborations | 1 | |||||||||||||||
| Upfront fee received | $ 100,000,000 | $ 1,000,000 | ||||||||||||||
| Number of units of accounting | 1 | |||||||||||||||
| Revenue recognized | 100,000,000 | 25,000,000 | 4,300,000 | 500,000 | 1,000,000 | |||||||||||
| Maximum amount of payments receivable | 320,000,000 | 800,000,000 | ||||||||||||||
| Cumulative amount of payments earned under collaborative arrangement | 6,500,000 | |||||||||||||||
| Collaborative payment earned | 750,000 | 500,000 | ||||||||||||||
| Uncured breach period | 60 days | |||||||||||||||
| Notice period for termination of agreement without cause | 180 days | |||||||||||||||
| Notice period for termination of agreement due to change of control | 30 days | |||||||||||||||
| Period of collaboration in research phase | 3 years | |||||||||||||||
| Final payment received | $ 4,300,000 | |||||||||||||||